Trial Profile
A real world study of Ranibizumab in patients with visual impairment from the french BOREAL cohort.
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 01 Mar 2022
Price :
$35
*
At a glance
- Drugs Ranibizumab (Primary)
- Indications Diabetic macular oedema
- Focus Therapeutic Use
- Acronyms BOREAL-DME
- 26 Aug 2018 Final results presented at the 34th International Conference on Pharmacoepidemiology and Therapeutic Risk Management
- 18 Sep 2017 New trial record
- 30 Aug 2017 Results (n=290) assessing BCVA in patients with visual impairment due to diabetic macular edema presented at the 33rd International Conference on Pharmacoepidemiology and Therapeutic Risk Management